Pacific Growth Keeps Equal-Weight on Quidel

Analyst Adam Chazan says he believes the suspension of Chiron's flu vaccine manufacturing license may benefit Quidel

Pacific Growth says the Chiron (CHIR ) news may benefit Quidel (QDEL ). It reiterated its equal-weight rating on Quidel shares.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.